Innovative Na 1.8 inhibitors are advancing through late-stage trials, with Onzotrigine showing superior efficacy and rapid onset in acute pain, and LTG-321 progressing in chronic pain. Strong market demand, robust funding, and a differentiated clinical profile position the pipeline for significant impact.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.